# Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy

> **NCT00813059** · PHASE2 · UNKNOWN · sponsor: **Mount Sinai Hospital, Canada** · enrollment: 10 (estimated)

## Conditions studied

- Non-arteritic Anterior Ischemic Optic Neuropathy

## Interventions

- **DRUG:** Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)

## Key facts

- **NCT ID:** NCT00813059
- **Lead sponsor:** Mount Sinai Hospital, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-02
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2012-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813059, "Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00813059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*